Medical treatments for male and female pattern hair loss

Journal of the American Academy of Dermatology

Volumn 59, Issue 4, 2008, Pages 547-566

  Rogers, Nicole E ^a   Avram, Marc R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; BUTANEDIOL; CYPROTERONE ACETATE; DERMATOLOGICAL AGENT; DROSPIRENONE; DUTASTERIDE; ETHINYLESTRADIOL; FINASTERIDE; KETOCONAZOLE; MINOXIDIL; NIOXIN; PLACEBO; PROCERIN; PROPYLENE GLYCOL; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; SABAL EXTRACT; SPIRONOLACTONE; TOPPIK; TRICOMIN; UNCLASSIFIED DRUG;

ALOPECIA; ALOPECIA AREATA; BLOOD PRESSURE; CANCER RISK; CLINICAL TRIAL; CLINODACTYLY; CONTACT DERMATITIS; CRYPTORCHISM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EJACULATION DISORDER; ERECTILE DYSFUNCTION; ERYTHEMA; EXFOLIATIVE DERMATITIS; FACE COARSENESS; FACE DISORDER; FACE DYSMORPHIA; GENDER; GYNECOMASTIA; HAIR LOSS; HAIR TRANSPLANTATION; HUMAN; HYPERTRICHOSIS; LIBIDO DISORDER; MALE TYPE ALOPECIA; MASTALGIA; NONHUMAN; OMPHALOCELE; PARESTHESIA; PERIORAL NUMBNESS; PHOTOTHERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; READING; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ALLERGY; SKIN DARKNESS; SKIN DISCOLORATION; SKIN IRRITATION; SKIN PRURITUS; SPERM; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; TRACTION ALOPECIA; WEIGHT GAIN;

ADULT; ALOPECIA; ANDROGEN ANTAGONISTS; AZASTEROIDS; DRUG THERAPY, COMBINATION; FEMALE; FINASTERIDE; HAIR; HUMANS; HYPERHIDROSIS; KETOCONAZOLE; MALE; MINOXIDIL; PHOTOTHERAPY; PROSTATE; SPERM COUNT; TRETINOIN;

EID: 51349156637     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.07.001     Document Type: Review

References (193)

1. Mehta P.K., Mamdani B., Sharsky R.M., Mahurkar S.D., and Dunea G. Severe hypertension. Treatment with minoxidil. JAMA 233 (1975) 249-252
2. Kosman M.E. Evaluation of a new antihypertensive agent: minoxidil. JAMA 244 (1980) 73-75
3. Meisheri K.D., Cipkus L.A., and Taylor C.J. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther 245 (1988) 751-760
4. Jacomb R.G., and Brunnberg F.J. The use of minoxidil in the treatments of severe essential hypertension: a report on 100 patients. Clin Sci Mol Med Suppl 3 (1976) 579s-581s
5. Devine B.L., Fife R., and Trust P.M. Minoxidil for severe hypertension after failure of other hypotensive drugs. Br Med J 2 (1977) 667-669
6. Dargie H.J., Dollery C.T., and Daniel J. Minoxidil in resistant hypertension. Lancet 2 (1977) 515-518
7. Pennisi A.J., Takahashi M., Bernstein B.H., Singsen B.H., Uittenbogaart C., Ettenger R.B., et al. Minoxidil therapy in children with severe hypertension. J Pediatr 90 (1977) 813-819
8. Jacobs D. Minoxidil experience in Australia: 1974-1980. Med J Aust 1 (1981) 477-478
9. Burton J.L., and Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol 101 (1979) 593-595
10. Zapacosta A.R. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med 303 (1980) 1480-1481
11. Fenton D.A., and Wilkinson J.D. Topical minoxidil in the treatment of alopecia areata. Br Med J 287 (1983) 1015-1017
12. Weiss V.C., West D.P., Fu T.S., Robinson L.A., Cook B., Cohen R.L., et al. Alopecia areata treated with topical minoxidil. Arch Dermatol 120 (1984) 457-463
13. Vanderveen E.E., Ellis C.N., Kang S., Case P., Headington J.T., Voorhees J.J., et al. Topical minoxidil for hair regrowth. J Am Acad Dermatol 11 (1984) 416-421
14. Burton J.L., Schutt W.H., and Caldwell I.W. Hypertrichosis due to diazoxide. Br J Dermatol 93 (1975) 707-711
15. Koblenzer P.J., and Baker L. Hypertrichosis lanuginose associated with diazoxide therapy in prepubertal children: a clinicopathologic study. Ann NY Acad Sci 150 (1968) 373-382
16. Wester R.C., Maibach H.I., Guy R.H., and Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalp: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 82 (1984) 515-517
17. Lachgar S., Charveron M., Gall Y., and Bonafe J.L. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 138 (1998) 407-411
18. Buhl A.E., Waldon D.J., Baker C.A., and Johnson G.A. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol 95 (1990) 553-557
19. Baker C.A., Uno H., and Johnson G.A. Minoxidil sulfation in the hair follicle. Skin Pharmacol 7 (1994) 335-339
20. Dooley T.P., Walker C.J., Hirshey S.J., Falany C.N., and Diani A.R. Localization of minoxidil sulfotransferase in rat liver and the outer root sheath of anagen pelage and vibrissa follicles. J Invest Dermatol 96 (1991) 65-70
21. Buhl A.E., Baker C.A., and Dietz A.J. Minoxidil sulfotransferase activity influences the efficacy of Rogaine topical solution (TS): enzyme studies using scalp and platelets. J Invest Dermatol 102 (1994) 534
22. Baden H.P., and Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol 81 (1983) 558-560
23. Han J.H., Kwon O.S., Chung J.H., Cho K.H., Eun H.C., and Kim K.H. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci 34 (2004) 91-98
24. Uno H., Cappas A., and Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 16 (1987) 657-658
25. Uno H. The stump-tailed macaque as a model for baldness: effects of minoxidil. Int J Cosmet Sci 8 (1986) 63-71
26. Cohen R.L., Alves M., Weiss V., West D.P., and Chambers D.A. Direct effects of minoxidil on epidermal cells in culture. J Invest Dermatol 82 (1984) 90-93
27. Mori O., and Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 17 (1990) 276-281
28. Uno H., Mori O., Cappas A., Buys C.M., and Fiedler-Weiss V.C. The effect of topical minoxidil on sequential histological changes in alopecia totalis and universalis. J Invest Dermatol 86 (1986) 512
29. Abell E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin Dermatol 6 (1988) 191-194
30. Headington J.T., and Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res 36 (1984) 1098-1106
31. Novak E., Franz T.J., Headington J.T., and Wester R.C. Topically applied minoxidil in baldness. Int J Dermatol 24 (1985) 82-87
32. Galbraith G.M., and Thiers B.H. In vitro suppression of human lymphocyte activity by minoxidil. Int J Dermatol 24 (1985) 249-251
33. Hordinsky M.K., Wietgrefe M.M., Sevenich E., Hallgren H., and Filipovich A.M. Immune function in alopecia areata patients applying 3% topical minoxidil. Clin Res 33 (1985) 646A
34. Weiss V.C., and West D.P. Topical minoxidil therapy and hair regrowth. Arch Dermatol 121 (1985) 191-192
35. Kvedar J.C., Baden H.P., and Levine L. Selective inhibition by minoxidil of prostacycline production by cells in culture. Biochem Pharmacol 37 (1988) 867-874
36. O'Barr T.P., Swanson E.W., Fitzpatrick J.E., and Corby D.G. Effect of minoxidil on platelet function and the synthesis of prostaglandins inplatelets. J Lab Clin Med 114 (1989) 575-578
37. Messenger A.G., and Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 150 (2004) 186-194
38. Bunker C.B., and Dowd P.M. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol 117 (1987) 668-669
39. Buhl A.E., Waldon D.J., Conrad S.J., Mulholland M.J., Shull K.L., Kubicek M.F., et al. Potassium channel conductance: a mechanism affecting hair growth in vitro and in vivo. J Invest Dermatol 98 (1992) 315-319
40. Buhl A.E., Conrad S.J., Waldon D.J., and Brunden M.N. Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 101 Suppl 1 (1993) 148S-152S
41. Nuck B.A., Fogelson S.L., and Lucky A.W. Topical minoxidil does not act as an antiandrogen in the flank organ of the golden Syrian hamster. Arch Dermatol 123 (1987) 59-61
42. Murad S., and Pinnell S.R. Suppression of fibroblast proliferation and lysyl hydroxylase activity by minoxidil. J Biol Chem 262 (1987) 11973-11978
43. Pinnell S.R., and Murad S. Effects of minoxidil on cultured human skin fibroblasts. Dermatologica 175 Suppl 2 (1987) 12-18
44. Price V.H., and Menefee E. Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of minoxidil. J Invest Dermatol 95 (1990) 683-687
45. Olsen E.A., DeLong E.R., and Weiner M.S. Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol 15 (1986) 30-37
46. Kreindler T.G. Topical minoxidil in early androgenetic alopecia. J Am Acad Dermatol 16 (1987) 718-724
47. Roberts J.L. Androgenetic alopecia: treatment results with topical minoxidil. J Am Acad Dermatol 16 (1987) 705-710
48. Olsen E.A., Weiner M.S., Amara I.A., and DeLong E.R. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol 22 (1990) 643-646
49. Price V.H., Menefee E., and Strauss P.C. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 41 (1999) 717-721
50. Olsen E.A., Dunlap F.E., Funicella T., Koperski J.A., Swinehart J.M., Tschen E.H., et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in man. J Am Acad Dermatol 47 (2002) 377-385
51. Lucky A.W., Picquadio D.J., Ditre C.M., Dunlap F., Kantor I., Pandya A.G., et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 50 (2004) 541-553
52. Olsen E.A., Whiting D., Bergfeld W., Miller J., Hordinsky M., Wanser R., et al. A multicenter, randomized, placebo-controlled double-blind clinical trial of a novel formulation of 5% topical minoxidil topical foam vs. placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 57 (2007) 767-774
53. Tsuboi R., Tanaka T., Nishikawa T., Ueki R., Yamada H., Katsuoka K., et al. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol 17 (2007) 37-44
54. Fenton D.A., and Wilkinson J.D. Alopecia areata treated with topical minoxidil. J Royal Soc Med 75 (1982) 963-965
55. Shi Y.P. Topical minoxidil in the treatment of alopecia areata and male-pattern alopecia. Arch Dermatol 122 (1986) 506
56. Vestey J.P., and Savin J.A. Topical minoxidil in alopecia areata: a double-blind trial. Br J Dermatol 113 (1985) 35
57. White S.I., and Friedmann P.S. Topical minoxidil lacks efficacy in alopecia areata. Arch Dermatol 121 (1985) 591
58. Fiedler V.C., and Buys C.M. Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. Dermatologica 175 Suppl 2 (1987) 29-35
59. Ranchoff R.E., Bergfeld W.F., Steck W.D., and Subichin S.J. Extensive alopecia areata: results of treatment with 3% topical minoxidil. Cleve Clin J Med 56 (1989) 149-154
60. Khoury E.L., Price V.H., Abdel-Salam M.M., Stern M., and Greenspan J.S. Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. J Invest Dermatol 99 (1992) 40-47
61. Kassimir J.J. Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. J Am Acad Dermatol 16 (1987) 685-687
62. Bouhanna P. Topical minoxidil used before and after laser hair transplantation. J Dermatol Surg Oncol 15 (1989) 50-53
63. Roenigk H.H., and Berman M.D. Topical 2% minoxidil with hair transplantation. Face 4 (1993) 213-216
64. Avram M.R., Cole J.P., Gandelman M., Haber R., Knudsen R., Leavitt M.T., et al. The potential role of minoxidil in the hair transplantation setting: roundtable consensus meeting of the 9th annual meeting of the International Society of Hair Restoration Surgery. Dermatol Surg 28 (2002) 894-900
65. Granai C.O., Frederickson H., Gajawski W., Goodman A., Goldstein A., and Baden H. The use of topical minoxidil to attempt to prevent alopecia from chemotherapy for gynecological malignancies. Eur J Gynaecol Oncol 12 (1991) 129-132
66. Rodriguez R., Machiavelli M., Leone B., Romero A., Cuevas M.A., Langhi M., et al. Minoxidil as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol 5 (1994) 769-770
67. Duvic M., Lemak N.A., Valero V., Hymes S.R., Farmer K.L., Hortobagyi G.N., et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35 (1996) 74-78
68. Khumalo N.P., and Ngwanya R.M. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol 21 (2007) 433-444
69. Franz T.J. Percutaneous absorption of minoxidil in man. Arch Dermatol 121 (1985) 203-206
70. Fiedler-Weiss V.C., West D.P., Buys C.M., and Rumsfield J.A. Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol 122 (1986) 180-182
71. Price V.H. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 16 3 Pt 2 (1987) 730-736
72. Clissold S.P., and Heel R.C. Topical minoxidil: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs 33 (1987) 107-122
73. Olsen E.A., and Weiner M.S. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol 17 (1987) 97-101
74. Dawber R.P., and Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol 17 (2003) 271-275
75. Peluso A.M., Misciali C., Vincenzi C., and Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol 136 (1997) 118-120
76. Rietschel R.L., and Duncan S.H. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol 16 (1987) 677-685
77. Degreef H., Hendrickx Y., and Dooms-Goossens A. Allergic contact dermatitis to minoxidil. Contact Derm 13 (1985) 194-195
78. Tosti A., Bardazzi F., dePadova M.P., Caponeri G.M., Melino M., and Veronisi S. Contact dermatitis to minoxidil. Contact Derm 13 (1985) 275-276
79. Valsecchi R., and Cainelli T. Allergic contact dermatitis from minoxidil. Contact Derm 17 (1987) 58-59
80. Alomar A., and Smandia J.A. Allergic contact dermatitis from minoxidil. Contact Derm 18 (1988) 51-52
81. Wilson C., Walkden V., Powell S., Shaw S., Wilkinson J., and Dawber R. Contact dermatitis in reaction to 2% topical minoxidil solution. J Am Acad Dermatol 24 (1991) 661-662
82. Ruas E., Concalo M., Figueiredo A., and Goncalo S. Allergic contact dermatitis from minoxidil. Contact Derm 26 (1992) 57-58
83. Ebner H., and Muller E. Allergic contact dermatitis from minoxidil. Contact Derm 32 (1995) 316-317
84. Friedman E.S., Friedman P.M., Cohen D.E., and Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol 46 (2002) 309-312
85. Stehle R., Ewing G., Rundegren J., and Kohut B. Update of minoxidil from a new foam formulation devoid of propylene glycol to hamster ear follicles (abstr). J Invest Dermatol 606 (2005) A101
86. Rundegren J., Westin A., and Kohut B. Hair growth efficacy assessment of a new topical minoxidil foam formulation in the stump-tail macaque (abstr). J Invest Dermatol 587 (2005) A98
87. Shapiro J. Safety of topical minoxidil solution: a one-year, prospective observational study. J Cutan Med Surg 7 (2003) 322-329
88. Campese V.M. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs 22 (1981) 257-278
89. Kaler S.G., Patrinos M.E., Lambert G.H., Myers T.F., Karlman R., and Anderson C.L. Hypertrichosis and congenital anomalies associated with maternal use of minoxidil. Pediatrics 79 (1987) 434-436
90. Rosa F.W., Idanpaan-Heikkila J., and Asanti R. Fetal minoxidil exposure. Pediatrics 80 (1987) 120
91. Veyrac G., Chiffoleau A., Bailly C., Baudot S., Beaudouin S., and Larousse C. Cutaneous application of minoxidil during pregnancy: hairy infant. [in French]. Therapie 50 (1995) 474-476
92. Rojansky N., Fasouliotis S.F., Ariel I., and Nadjari M. Extreme caudal agenesis. Possible drug-related etiology?. J Reprod Med 47 (2002) 241-245
93. Smorlesi C., Caldarella A., Caramelli L., Di Lollo S., and Moroni F. Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Res A Clin Mol Teratol 67 (2003) 997-1001
94. Ferry J.J., Forbes K.K., VanderLugt J.T., and Szpunar G.J. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clin Pharmacol Ther 47 (1990) 439-446
95. Bazzano G.S., Terezakis N., and Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 15 (1986) 880-883
96. Shin H.S., Won C.H., Lee S., Kwon O.S., Kim K.H., and Eun H.C. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative trial. Am J Clin Dermatol 8 (2007) 285-290
97. Bergfeld W.F. Retinoids and hair growth. J Am Acad Dermatol 39 (1998) S86-S89
98. Kligman A.M., Grove G.L., Hirose R., and Leyden J.J. Topical tretinoin for photoaged skin. J Am Acad Dermatol 15 (1986) 836-859
99. Kwon O.S., Pyo H.K., Oh Y.J., Han J.H., Lee S.R., Chung J.H., et al. Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro. J Korean Med Sci 22 (2007) 283-289
100. In: Runes D.D., and Kiernan T. (Eds). Hippocrates: the theory and practice of medicine (1964), Philosophical Library, New York
101. Wilson J.D., Griffin J.E., and Russell D.W. Steroid 4 alpha reductase 2 deficiency. Endocr Rev 14 (1993) 577-593
102. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., and Russell D.W. Tissue distribution and ontogeny of steroid 5-alpha-reductase insoenzyme expression. J Clin Invest 92 (1993) 903-910
103. Rhodes L., Harper J., Uno H., Gaito G., Audette-Arruda J., Kurata S., et al. The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone in adult male and female stump-tail macaques (Macaca arctoides). J Clin Endocrinol Metab 29 (1994) 991-996
104. Dallob A.L., Sadick N.S., Unger W., Lipert S., Geissert L.A., Gregoire S.L., et al. The effect of finasteride, a 5-alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metabol 79 (1994) 703-706
105. Drake L., Hordinsky M., Fiedler V., Swinehart J., Unger W.P., Cotterill P.C., et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 41 (1999) 550-554
106. Roberts J.L., Fiedler V., Imperato-McGinley J., Whiting D., Olsen E., Shupack J., et al. Clinical dose ranging studies with finasteride, a type 2 5-alpha reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 41 (1999) 555-563
107. Kawashima M., Hayashi N., Igarashi A., Kitahara H., Maeguchi M., Mizuno A., et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol 14 (2004) 247-254
108. Propecia [package insert] (2004), Merck & Co, Inc, Whitehouse Station, NJ
109. McClellan K.J., and Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs 57 (1999) 111-126
110. Kaufman K.D., Olsen E.A., Whiting D., Savin R., DeVillez R., Bergfeld W., et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 39 (1998) 578-589
111. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 12 (2002) 38-49
112. Leyden J., Dunlap F., Miller B., Winters P., Lebwohl M., Hecker D., et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 40 6 Pt 1 (1999) 930-937
113. Stough D.B., Rao N.A., Kaufman K.D., and Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 12 (2002) 32-37
114. Leavitt M., Perez-Meza D., Rao N.A., Barusco M., Kaufman K.D., and Ziering C. Effects of finasteride (1 mg) on hair transplant. J Dermatol Surg 31 (2005) 1268-1276
115. Van Neste D., Fuh V., Sanchez Pedreno P., Lopez-Bran E., Wolff H., Whiting D., et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 143 (2000) 804-810
116. Price V.H., Menefee E., Sanchez M., Ruane P., and Kaufman K.D. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 46 (2002) 517-523
117. Price V.H., Menefee E., Sanchez M., and Kaufman K.D. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 55 (2006) 71-74
118. Price V.H., Roberts J.L., Hordinsky M., Olsen E.A., Savin R., Bergfeld W., et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 43 (2000) 768-776
119. Shum K.W., Cullen D.R., and Messenger A.G. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 47 (2002) 733-739
120. Olsen E.A., Hordinsky M., Roberts J.L., and Whiting D.A. Dermatologica Consortium for Women's Health. Female pattern hair loss. J Am Acad Dermatol 47 (2002) 795
121. Iorizzo M., Vincenzi C., Voudouris S., Piraccini B.M., and Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol 142 (2006) 298-302
122. Kohler C., Tschumi K., Bodmer C., Schneiter M., and Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol 23 (2007) 142-145
123. D'Amico A.V., and Roehrborn C.G. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenetic alopecia: a randomized controlled trial. Lancet Oncol 8 (2007) 21-25
124. Thompson I.M., Chi C., Ankerst D.P., Goodman P.J., Tangen C.M., Lippman S.M., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
125. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
126. De Vere, and White R.W. Finasteride for chemoprevention of prostate cancer: why has it not been embraced?. J Clin Oncol 25 (2007) 2999-3000
127. Lucia M.S., Epstein J.I., Goodman P.J., Darke A.K., Reuter V.E., Civantos F., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1375-1383
128. Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 Suppl (1997) 16-22
129. Petraki C.D., and Sfikas C.P. Histopathologic changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 22 (2007) 107-118
130. Cohen Y.C., Liu K.S., Heyden N.L., Carides A.D., Anderson K.M., Daifotis A.G., et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1366-1374
131. Serfling R., Shulman M., Thompson G.L., Xiao Z., Benaim E., Roehrborn C.G., et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5-alpha reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 177 (2007) 2352-2356
132. Kulkarni G.S., Al-Azab R., Lockwood G., Toi A., Evans A., Trachtenberg J., et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175 (2006) 505-509
133. Andriole G.L., Humphrey P.A., Serfling F.J., and Grubb R.L. High-grade prostate cancer in the prostate cancer prevention trial: fact or artifact?. J Natl Cancer Inst 99 (2007) 1355-1356
134. Overstreet J.W., Fug V.L., Gould J., Howards S.S., Lieber M.M., Hellstrom W., et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 162 (1999) 1295-1300
135. Amory J.K., Wang C., Swerdloff R.S., Anawalt B.D., Matsumoto A.M., Bremner W.J., et al. The effect of 5alpha reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 92 (2007) 1659-1665
136. Collodel G., Scapigliati G., and Moretti E. Spermatozoa and chronic treatment with finasteride: a TEM and FISH study. Arch Androl 53 (2007) 229-233
137. Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril 2007 Dec 3 (Epub ahead of print).
138. Wilton L., Pearce G., Edet E., Freemantle S., Stephens M.D.B., and Mann R.D. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol 78 (1996) 379-384
139. Mondaini N., Gontero P., Giubilei G., Lombardi G., Cai T., Gavazzi A., et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. J Sex Med 4 (2007) 1708-1712
140. Altomare G., and Capella G.L. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 29 (2002) 665-669
141. Rahimi-Ardabili B., Pourandarjani R., Habibollahi P., and Mualeki A. Finasteride-induced depression: a prospective study. BMC Clin Pharmacol 6 (2006) 7
142. Bramson H.N., Hermann D., Batchelor K.W., Lee F.W., James M.K., and Frye S.V. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5-AR. J Pharmacol Exp Ther 282 (1997) 1496-1502
143. Clark R.V., Hermann D.J., Cunningham G.R., Wilson T.H., Morrill B.B., and Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179-2184
144. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., Andriole G., ARIA3001, ARIA3002, and and ARIA3003 Study Investigators. Efficacy and safety of dual inhibitor of 5-α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
145. Roehrborn C.G., Marks L.S., Fenter T., Freedman S., Tuttle J., Gittleman M., et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63 (2004) 709-715
146. Olsen E.A., Hordinsky M., Whiting D., Stough D., Hobbs S., Ellis M.L., et al. The importance of dual 5-alpha reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs. finasteride. J Am Acad Dermatol 55 (2006) 1014-1023
147. Olszewska M., and Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 4 (2005) 637-640
148. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol 6 (2007) 9-13
149. Bruchovsky N., Sadar M.D., Akakura K., Goldenberg S.L., Matsuoka K., and Rennie P.S. Characterization of 5-α-reductases gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 59 (1996) 397-404
150. Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., et al. 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019-2025
151. Marihart S., Harik M., and Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5α reductase. Rev Urology 7 (2005) 203-210
152. Andriole G.L., Humphrey P., Ray P., Gleave M.E., Trachtenberg J., Lazer C.B., et al. Effect of the dual 5-alpha reductase inhibitor dutasteride on markers of tumor progression in prostate cancer. J Urol 172 (2004) 915-919
153. Andriole G.L., Roehrborn C., Schulman C., Slawin K.M., Somerville M., and Rittmaster R.S. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537-541
154. Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172 (2004) 1314-1317
155. Gomella L.G. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 15 (2005) 29-32
156. Fleshner N., Gomella L.G., Cookson M.S., Finelli A., Evans A., Taneja S.S., et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Comtemp Clin Trials 28 (2007) 763-769
157. Andriole G.L., and Kirby R. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 (2003) 82-88
158. Avodart [package insert] (2005), GlaxoSmithKline, Research Triangle Park, NC
159. Sinclair R., Wewerinke M., and Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152 (2005) 466-473
160. Vexiau P., Chaspoux C., Boudou P., Fiet J., Jouanique C., Hardy N., et al. Effects of minoxidil 2% versus cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month, randomized trial. Br J Dermatol 146 (2002) 992-999
161. Pierard-Franchimont C., De Doncker P., Cauwenbergh G., and Pierard G.E. Ketoconazole shampoo: effect of long-term use in androgenetic alopecia. Dermatology 196 (1998) 474-477
162. Jiang J., Tsuboi R., Kojima Y., and Ogawa H. Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. J Dermatol 32 (2005) 243-247
163. Beetens J.R., Loots W., Somers Y., Coene M.C., and De Clerk F. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 35 (1986) 883-891
164. Van Cutsem J., Van Gerven F., Cauwenbergh G., Odds F., and Janssen P.A.J. The anti-inflammatory effects of ketoconazole. J Am Acad Dermatol 25 (1991) 257-261
165. Hugo Perez B.S. Ketoconazole as an adjuct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses 62 (2004) 112-115
166. Inui S., and Itami S. Reversal of androgenic alopecia by topical ketoconzole: relevance of anti-androgenic activity. J Dermatol Sci 45 (2007) 66-68
167. In: Wolverton S.E. (Ed). Comprehensive dermatologic drug therapy and treatment of skin disease (2002), Elsevier, St. Louis, MO
168. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocrinol Rev 7 (1986) 409-420
169. Sonino N., Scaroni C., Biason A., Boscaro M., and Mantero F. Low-dose ketoconazole treatment in hirsute women. J Endocrinol Invest 13 (1990) 35-40
170. Mester E., Szende B., and Gartner P. The effect of laser beams on the growth of hair in mice. Radiobiol Radiother 9 (1968) 621-626
171. Al-Watban F.A., Zhang X.Y., and Andres B.L. Low-level laser therapy enhances wound healing in diabetic rats: a comparison of different lasers. Photomed Laser Surg 25 (2007) 72-77
172. Hamblin MR, Demidova TN. Mechanisms of low level light therapy. Proc SPIE, Vol. 6140. February 10, 2006:1-12.
173. Lampl Y., Zivin J.A., Fisher M., Lew R., Welin L., Dahlof B., et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the Neurothera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38 (2007) 1843-1849
174. Oron U., Ilic S., DeTaboada L., and Streeter J. Ga-As (808-nm) laser irradation enhances ATP production in human neuronal cells in culture. Photomed Laser Surg 25 (2007) 180-182
175. Gavish L., Asher Y., Becker Y., and Kleinman Y. Low level laser irradiation stimulates mitochondrial membrane potential and disperses subnuclear promyelocytic leukemia protein. Laser Surg Med 35 (2004) 369-376
176. Yu W., Naim J.O., McGowan M., Ippolito K., and Lanzafame R.J. Photomodulation of oxidative metabolism and electron chain enzymes in rat liver mitochondria. Photochem Photobiol 66 (1997) 866-871
177. Satino J.L., and Markou M. Hair regrowth and increased hair tensile strength using the HairMax LaserComb for low-level laser therapy. Intl J Cosmet Surg Aesthet Dermatol 5 (2003) 113-117
178. Avram M.R., Leonard Jr. R.T., Epstein E.S., Williams J.L., and Bauman A.J. The current role of laser/light sources in the treatment of male and female pattern hair loss. J Cosmet Laser Ther 9 (2007) 27-28
179. Habib F.K., Ross M., Ho C.K., Lyons V., and Chapman K. Serenoa repens (Permixon) inhibits the 5-alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114 (2005) 190-194
180. Wilt T., Ishani A., and MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 3 (2002) CD001423
181. Bent S., Kane C., Shinohara K., Neuhaus J., Hudes E.S., Goldberg H., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 (2006) 557-566
182. Prager N., Bickett K., French N., and Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 8 (2002) 143-152
183. Colombo V.E., Gerber F., Bronhofer M., and Floersheim G.L. Treatment of brittle fingernails and onychoschizia with biotin: scanning electron microscopy. J Am Acad Dermatol 23 6 Pt 1 (1990) 1127-1132
184. Limat A., Suormala T., Hunziker T., Waelti E.R., Braathen L.R., and Baumgartner R. Proliferation and differentiation of cultured human follicular keratinocytes are not influenced by biotin. Arch Dermatol Res 288 (1996) 31-38
185. Nioxin web site. Available at: www.nioxin.com. Accessed July 15, 2008.
186. Procerin web site. Available at: www.procerin.com. Accessed July 15, 2008.
187. Tricomin web site. Available at: www.tricomin.com. Accessed July15, 2008.
188. Pyo H.K., Yoo H.G., Won C.H., Lee S.H., Kang Y.J., Eun H.C., et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 30 (2007) 834-839
189. Trachy R.E., Fors T.D., Pickart L., and Uno H. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann NY Acad Sci 642 (1991) 468-469
190. Toppik web site. Available at: www.toppik.com. Accessed July 15, 2008.
191. Khandpur S., Suman M., and Reddy B.S. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 29 (2002) 489-498
192. Diani A.R., Mulholland M.J., Shull K.L., Kubicek M.F., Johnson G.A., Schostarez H.J., et al. Hair growth effects of oral administration of finasteride, a steroid 5-alpha reductase inhibitor, alone and in combination with topical minoxidil in the balding stump-tail macaque. J Clin Endocrinol Metab 74 (1992) 345-350
193. Tosti A., Iorizzo M., and Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch Dermatol 139 (2003) 1221-1222